An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells as Therapy for Stress Urinary Incontinence

NCT00847535 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Stress Urinary Incontinence
Cell Therapy

Interventions

BIOLOGICAL: autologous muscle cell injection

Sponsor

Cook MyoSite